A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

Key Inclusion Criteria: * Participants must have a PiZZ genotype confirmed at screening * Plasma AAT levels indicating severe deficiency at screening Key Exclusion Criteria: * History of a medical condition that could negatively impact the ability to complete the study * Solid organ, or hematological transplantation or is currently on a transplant list * History of use of gene therapy or Ribonucleic acid interference (RNAi) therapy at any time previously * Participants for whom discontinuation of augmentation therapy is not considered to be in their best interest, based on the clinical judgement of the treating physician Other protocol defined Inclusion/Exclusion criteria may apply.